Effects of Neoadjuvant Chemotherapy Toxicity and Postoperative Complications on Short-term and Long-term Outcomes After Curative Resection of Gastric Cancer

• Published in: Journal of gastrointestinal surgery Vol. 24; no. 6; pp. 1278 - 1289
• Main Authors: Wu, Chaorui, Wang, Nianchang, Zhou, Hong, Wang, Tongbo, Mao, Qikun, Zhang, Xiaojie, Zhao, Dongbing
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.06.2020; Springer Nature B.V
• Subjects: Cancer surgery; Cancer therapies; Chemotherapy; Gastrectomy - adverse effects; Gastric cancer; Gastroenterology; Hospitals; Humans; Lymphocytes; Medical prognosis; Medicine; Medicine & Public Health; Metastasis; Morbidity; Neoadjuvant Therapy - adverse effects; Neutrophils; Original Article; Postoperative Complications - epidemiology; Postoperative period; Retrospective Studies; Short term; Stomach Neoplasms - drug therapy; Stomach Neoplasms - surgery; Studies; Surgery; Neoadjuvant chemotherapy; Chemotherapy toxicity; Prognosis; Postoperative complication; Gastric cancer
• ISSN: 1091-255X; 1873-4626
• DOI: 10.1007/s11605-019-04257-2

Background Whether neoadjuvant chemotherapy (NAC) increased the risk of postoperative morbidities for patients with locally advanced gastric cancer (GC) is unknown. Whether neoadjuvant chemotherapy toxicity (NCT) and postoperative complications (POCs) correlate with short-term and long-term outcomes also remains unclear. We aimed to evaluate the role of NAC on the development of POCs, as well as the impact of NCT and POCs on postoperative and oncologic outcomes in curatively resected GC treated with NAC. Methods This study retrospectively reviewed 230 patients who underwent curative gastrectomy for locally advanced GC (clinically T3/4 or N+) after NAC between 2006 and 2016. Five hundred patients undergoing upfront and curative surgery were selected as a control group. After matching, the incidence of POCs was compared between two groups. In the NAC group, clinicopathological characteristics of patients who experienced POCs were compared to those who did not. Logistic and Cox multivariate regression analyses were used to examine factors associated with POCs, disease-free survival (DFS), and overall survival (OS). Results Following matching, 230 and 230 patients treated with surgery plus NAC and upfront surgery remained, respectively. The incidence of POCs was 28.7% and 24.3%, respectively ( p  = 0.290). In the NAC group, NCT (OR [odds ratio] 22.968, 95% CI [confidence interval] 2.948–> 99, p  = 0.003) and operation time (OR 1.006, 95% CI 1.001–1.011, p  = 0.021) were independent predictive factors of POCs. NCT did not affect oncologic outcomes. The Cox regression model demonstrated that POCs were independently associated with worse DFS (HR [hazard ratio] 2.128, 95% CI 1.240–3.653, p  = 0.006) but not OS for patients treated with NAC. Conclusions The administration of NAC is not associated with an elevated risk of POCs. For patients treated with NAC, NCT is an independent predictor of POCs, but does not affect oncologic outcomes. POCs is independently associated with worse DFS but not OS. NAC should be considered a safe approach in patients who have locally advanced GC. Strategies to minimize chemotherapy toxicity and postoperative morbidities associated with NAC are warranted.